CLUE腹腔和盆腔手术后静脉血栓栓塞风险仪:患者风险因素成分的验证。

IF 7.4 1区 医学 Q1 HEMATOLOGY
Kari A O Tikkinen, Deborah M Siegal, P J Devereaux, Sara V Tornberg, Flavia K Borges, Sandra Ofori, Jehonathan Pinthus, Bobby Shayegan, Lauri I Lavikainen, Gordon H Guyatt, Pavel S Roshanov
{"title":"CLUE腹腔和盆腔手术后静脉血栓栓塞风险仪:患者风险因素成分的验证。","authors":"Kari A O Tikkinen, Deborah M Siegal, P J Devereaux, Sara V Tornberg, Flavia K Borges, Sandra Ofori, Jehonathan Pinthus, Bobby Shayegan, Lauri I Lavikainen, Gordon H Guyatt, Pavel S Roshanov","doi":"10.1182/bloodadvances.2024015515","DOIUrl":null,"url":null,"abstract":"<p><p>Venous thromboembolism (VTE) remains a major postoperative risk. Systematic reviews have established procedure-specific VTE risk estimates, which form one component of the CLUE Post-Surgery VTE Risk Instrument. The instrument also incorporates patient-level factors-age (≥75 years), BMI (≥35 kg/m²), and prior VTE-to stratify overall risk. However, the patient risk factor component has not been formally validated. We therefore conducted the validation using data from the VISION study, a prospective, international cohort of 11,636 patients undergoing major general abdominal, urologic, or gynecologic surgery. Thirty-day postoperative VTE incidence was analyzed using modified Poisson regression. The instrument classified patients as low (72%), medium (25%), and high (4%) risk factor categories. VTE occurred in 97 patients (0.8%). Compared to the low-risk group, the relative risks of VTE was 1.56 (95% confidence interval, 1.01-2.43) for medium-risk and 3.60 (1.90-6.83) for high-risk patients. Among patients who did not receive antithrombotic medication, relative risks increased to 1.91 for medium-risk and 5.41 for high-risk patients. The CLUE Post-Surgery VTE Risk Instrument, using three widely available patient-level factors, accurately classifies patients into substantially different categories of relative VTE risk. This validated patient component complements procedure-specific absolute risk estimates derived from prior systematic reviews. To support evidence-based thromboprophylaxis decisions the instrument is now available through an interactive online platform.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The CLUE Post-Surgery VTE Risk Instrument for Abdominal and Pelvic Surgery: Validation of Patient Risk Factor Component.\",\"authors\":\"Kari A O Tikkinen, Deborah M Siegal, P J Devereaux, Sara V Tornberg, Flavia K Borges, Sandra Ofori, Jehonathan Pinthus, Bobby Shayegan, Lauri I Lavikainen, Gordon H Guyatt, Pavel S Roshanov\",\"doi\":\"10.1182/bloodadvances.2024015515\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Venous thromboembolism (VTE) remains a major postoperative risk. Systematic reviews have established procedure-specific VTE risk estimates, which form one component of the CLUE Post-Surgery VTE Risk Instrument. The instrument also incorporates patient-level factors-age (≥75 years), BMI (≥35 kg/m²), and prior VTE-to stratify overall risk. However, the patient risk factor component has not been formally validated. We therefore conducted the validation using data from the VISION study, a prospective, international cohort of 11,636 patients undergoing major general abdominal, urologic, or gynecologic surgery. Thirty-day postoperative VTE incidence was analyzed using modified Poisson regression. The instrument classified patients as low (72%), medium (25%), and high (4%) risk factor categories. VTE occurred in 97 patients (0.8%). Compared to the low-risk group, the relative risks of VTE was 1.56 (95% confidence interval, 1.01-2.43) for medium-risk and 3.60 (1.90-6.83) for high-risk patients. Among patients who did not receive antithrombotic medication, relative risks increased to 1.91 for medium-risk and 5.41 for high-risk patients. The CLUE Post-Surgery VTE Risk Instrument, using three widely available patient-level factors, accurately classifies patients into substantially different categories of relative VTE risk. This validated patient component complements procedure-specific absolute risk estimates derived from prior systematic reviews. To support evidence-based thromboprophylaxis decisions the instrument is now available through an interactive online platform.</p>\",\"PeriodicalId\":9228,\"journal\":{\"name\":\"Blood advances\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood advances\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/bloodadvances.2024015515\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024015515","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

静脉血栓栓塞(VTE)仍然是术后的主要风险。系统评价已经建立了特定手术的静脉血栓栓塞风险评估,这是CLUE术后静脉血栓栓塞风险工具的一个组成部分。该仪器还纳入患者水平因素-年龄(≥75岁)、BMI(≥35 kg/m²)和既往vte -以对总体风险进行分层。然而,患者风险因素成分尚未得到正式验证。因此,我们使用VISION研究的数据进行了验证,VISION研究是一项前瞻性国际队列研究,纳入了11,636名接受腹部、泌尿外科或妇科手术的患者。术后30天静脉血栓栓塞发生率采用改良泊松回归分析。该仪器将患者分为低(72%)、中(25%)和高(4%)危险因素类别。静脉血栓栓塞97例(0.8%)。与低危组相比,中危组VTE的相对危险度为1.56(95%可信区间1.01 ~ 2.43),高危组为3.60(95%可信区间1.90 ~ 6.83)。在未接受抗栓药物治疗的患者中,中危患者的相对危险度增加到1.91,高危患者的相对危险度增加到5.41。CLUE术后静脉血栓栓塞风险仪,使用三个广泛可用的患者水平因素,准确地将患者划分为不同的静脉血栓栓塞相对风险类别。这一经过验证的患者成分补充了先前系统评价得出的特定于手术的绝对风险估计。为了支持基于证据的血栓预防决策,该仪器现在可通过交互式在线平台获得。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The CLUE Post-Surgery VTE Risk Instrument for Abdominal and Pelvic Surgery: Validation of Patient Risk Factor Component.

Venous thromboembolism (VTE) remains a major postoperative risk. Systematic reviews have established procedure-specific VTE risk estimates, which form one component of the CLUE Post-Surgery VTE Risk Instrument. The instrument also incorporates patient-level factors-age (≥75 years), BMI (≥35 kg/m²), and prior VTE-to stratify overall risk. However, the patient risk factor component has not been formally validated. We therefore conducted the validation using data from the VISION study, a prospective, international cohort of 11,636 patients undergoing major general abdominal, urologic, or gynecologic surgery. Thirty-day postoperative VTE incidence was analyzed using modified Poisson regression. The instrument classified patients as low (72%), medium (25%), and high (4%) risk factor categories. VTE occurred in 97 patients (0.8%). Compared to the low-risk group, the relative risks of VTE was 1.56 (95% confidence interval, 1.01-2.43) for medium-risk and 3.60 (1.90-6.83) for high-risk patients. Among patients who did not receive antithrombotic medication, relative risks increased to 1.91 for medium-risk and 5.41 for high-risk patients. The CLUE Post-Surgery VTE Risk Instrument, using three widely available patient-level factors, accurately classifies patients into substantially different categories of relative VTE risk. This validated patient component complements procedure-specific absolute risk estimates derived from prior systematic reviews. To support evidence-based thromboprophylaxis decisions the instrument is now available through an interactive online platform.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信